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On 31 December, 2019, a cluster of 27 pneumonia cases of unknown etiology was reported by Chinese 
health authorities in Wuhan City (China). In particular, for almost all cases, an exposition to the Wuhan's 
Huanan Seafood Wholesale Market was found and, thus, the market was considered the most probable source 
of the virus outbreak [1]. Chinese health authorities have taken prompt public health measures, including 
intensive surveillance, epidemiological investigations, and closure of the market on 1 January, 2020 (Figure 1). 
On 9 January, 2020, the Chinese Government reported that the cause of the outbreak was a novel 
coronavirus, recently named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) [2], and was 
responsible for a disease defined COVID-19 (novel coronavirus disease 2019). This virus has been detected as 
the causative agent for 15 of the 59 pneumonia cases [3].  
From that date, an increasing number of studies have been published and several international 
institutions (World Health Organization, Centers for Disease Control and Prevention, European Centers for 
Disease Control and Prevention) have provided findings supporting a rapid increase in the general 
knowledge. However, despite these significant improved data, many questions about the new coronavirus 
remain, and answers could be strategic for programming and designing public health interventions. 
 
Figure 1. Timeline of the key events observed in the first month of the 2019 severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) outbreak. 
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SARS-CoV-2 was found to be a β-Coronavirus of group 2B with at least 70% similarity in genetic sequence 
to SARS-CoV-1, but sufficiently divergent to be considered a new human-infecting betacoronavirus (Table 1) 
[4]. It is highly probable that genome differences between SARS-CoV-1 and SARS-CoV-2 could be responsible 
for the different functionality and pathogenesis; thus, further studies could significantly help to solve this gap. 
The genetic sequence of the SARS-CoV-2 has been shared on 10 January, 2020, in order to allow the production 
of specific diagnostic PCR tests in different countries for detecting the novel infection [5].  
The evident convergence between SARS-CoV-2 and bat coronavirus (at least 96% identical at the whole-
genome level) seems to suggest that bats could be the original host [6]. A possible role of civets, snakes, and 
pangolins is not excluded as potential intermediate hosts, and it is clear that tracking the path of the virus 
could be crucial for preventing further exposure and outbreaks in the future. 
The SARS-CoV-2 RNA sequences have been found to have limited variability and the estimated mutation 
rates in coronavirus, which SARS-CoV-2 phylogenetically links to, are moderate to high, compared to the 
others in the category of single-stranded RNA viruses [7]. However, an accurate measure of the mutation rate 
for SARS-CoV-2 has not been calculated and the evaluation of its genetic evolution over time could have 
important implications for strategic planning in the prevention, as well as in the development of vaccines and 
antibodies-based therapies. 
Another important key point is the role of humoral immunity that, as for other coronavirus, might not be 
strong or long-lasting enough to keep patients safe from contracting the disease again. 
After infection occurred, incubation has been estimated to vary from 5 to 6 days, with a range of up to 14 
days [8]. However, the knowledge of the true incubation time could improve the estimates of the rates of 
asymptomatic and subclinical infections among immunocompetent individuals; thus, increasing the 
specificity in detecting COVID-19 cases. Additionally, it could significantly change the forecasting projection 
models on the worldwide outbreak evolution.  
In this sense, recently published studies have estimated a basic reproductive number of 3.28, exceeding 
the initial World Health Organization (WHO) estimates of 1.4 to 2.5 [9]. The basic reproductive number is an 
indication of viral transmissibility, representing the average number of new infections generated by a single 
infectious person in a totally naïve population; thus, when it decreases below 1, the outbreak can be considered 
under control. Moreover, there are evidences that SARS-CoV-2 appears to have been transmitted during the 
incubation period of patients in whom the illness was brief and nonspecific, whereas the detection of SARS-
CoV-2 with a high viral load in the sputum of convalescent patients arouse concern about prolonged shedding 
of the virus after recovery [10].  
In symptomatic COVID-19 patients, illness may evolve over the course of a week or longer, beginning 
with mild symptoms that progress (in some cases) to the point of dyspnea and shock [11]. Most common 
complaints are fever (almost universal), cough, which may or may not be productive, whereas myalgia and 
fatigue are relatively common conditions [12]. 
The updated case fatality rate of diagnosed cases is 2.3%, with an increasing risk in subjects aged 60 and 
older (3.6% in subjects 60–69 years old; 8% in subjects 70–79 years old; and 14.8% in subjects aged 80 and 
older), and those with comorbidities (case fatality rate in healthy subjects was 0.9%) [13]. Moreover, fatality 
rates seem to be decreasing over time (15.6%, 1–10 January, 2020; 5.7%, 11–20 January, 2020; 1.9%, 21–31 
January, 2020; 0.8% after 1 February, 2020) although this finding could be due to the increasing detection of 
“mild” cases in the general population or to a better management of the disease [14]. 
Unfortunately, to date, there are no vaccines against SARS-CoV-2, and there is the awareness that several 
months may be required to undergo extensive testing, and determine vaccine safety and efficacy before a 
potential wide use. Similarly, there is no single specific antiviral therapy; COVID-19 and the main treatments 
are supportive care (e.g., supportive therapy and monitoring—oxygen therapy and fluid management). In the 
last days, recombinant interferon (IFN) with ribavirin and infusions of blood plasma from people who have 
recovered from the COVID-19 are under evaluation, to treat infected subjects with encouraging results [14]. 
In conclusion, it is evident that in just a few weeks, the international scientific community has been 
involved in producing well-documented evidences in order to increase general knowledge about 
epidemiology, immunopathology, prevention, and treatment of COVID-19. However, many doubts about the 
new coronavirus remain, whereas there is the conviction that finding and sharing answers to these questions 
could represent a major challenge for public health control of a possible global SARS-CoV-2 outbreak.  
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Table 1. Summary of the scientific evidences, suggestions, and pending questions on the 2019 SARS-CoV-2 outbreak. 
 Documented evidences Scientific suggestions Pending questions 
Causative 
Agent 
Family of Coronaviridae (genus: 
Betacoronavirus) enveloped positive single-
stranded RNA [4,15]. 
  
Virus 
emergence 31 December, 2019 [1]. 
Emergence of SARS-CoV-2 into the human 
population likely occurred in mid-
November 2019 [16]. 
 
Virus 
phylogenesis 
SARS-CoV-2 is genetically very close to 
SARS-CoV, but sufficiently divergent to be 
considered a new human-infecting 
betacoronavirus [4]. 
 
Genome differences between SARS-CoV and 
SARS-CoV-2 could be responsible for the 
different functionality and pathogenesis. 
Virus hosts 
SARS-CoV-2 is 96% identical at the whole-
genome level to a bat coronavirus [4]. 
 
Cat civets, snakes, and pangolins are 
indicated as potential intermediate hosts. 
Tracking the path of the virus could be crucial 
for preventing further exposure and 
outbreaks in the future. 
Virus mutation 
rate and 
adaptation  
 
The SARS-CoV-2 RNA sequences have 
limited variability and the estimated 
mutation rates in coronavirus, which SARS-
CoV-2 phylogenetically links to, are 
moderate to high compared to the others in 
the category of ssRNA viruses [7]. In 
healthcare workers, severity of disease 
showed a decreasing trend over time 
(critical or severe presentation was 
observed in 45%, 1–10 January, 2020; 19.7%, 
11–20 January, 2020; 14.4%, 21–31 January, 
2020; 8.7% after 1 February, 2020) [13]. 
The outbreak could be initiated from either a 
single introduction into humans or from very 
few animal-to-human transmission events. 
How SARS-CoV-2 evolves over time could 
have important implications for both strategic 
planning in public health interventions, 
prevention of, and development of vaccines 
and antibodies. 
Virus 
environmental 
persistence 
 
On inanimate surfaces, human 
coronaviruses can remain infectious for up 
to 9 days. A surface disinfection with 0.1% 
sodium hypochlorite, 0.5% hydrogen 
peroxide, or 62%–71% ethanol can be 
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regarded as effective against coronaviruses 
within 1 min [15,17]. 
Virus spreading 
to human  
SARS-CoV-2 spreads from person-to-person 
via respiratory droplets (coughs or sneezes) 
and possibly also via contaminated hands 
or surfaces. Close contact (within about 6 
feet) increases risk of transmission [18]. 
The risk of transmission seems to be 
proportional to the severity of patient 
symptoms [18]. 
 
Immunity 
duration 
  
As for other coronaviruses, in infected 
patients, humoral immunity might not be 
strong or long-lasting enough to keep them 
from contracting the disease again. 
Incubation 
period 
Current estimates suggest a mean 
incubation period of 6.4 days (95% credible 
interval: 5.6–7.7), with a range from 2.1 to 
11.1 days (2.5th to 97.5th percentile) [19]. To 
date, the maximum observed incubation 
period was 14 days [8]. 
 
A recent modelling study confirmed that it 
remains prudent to consider the incubation 
period of at least 14 days [20]. 
A longer incubation time may lead to a high 
rate of asymptomatic and subclinical infection 
among immunocompetent individuals. This 
finding could represents a key question for 
setting length of surveillance period for each 
at risk patient. 
Basic 
reproductive 
number 
A basic reproductive number of 3.28 has 
been estimated by a review (range between 
different studies 1.95 to 6.49) [9]. 
 
It is important to further assess the reason for 
the higher basic reproductive number values 
estimated by some mathematical studies. 
Reproductive number estimations produced 
at later stages can be expected to be more 
reliable, as they build upon more case data 
and include the effect of awareness and 
intervention. Variations in reproduction 
number could also be found over time, 
according to an improving capacity to detect 
cases. 
Duration of the 
disease 
  
To date, there are no evidences on this key 
point. The detection of SARS-CoV-2 and a 
high sputum viral load in a convalescent 
patient arouse concern about prolonged 
shedding of SARS-CoV-2 after recovery [10].  
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Asymptomatic 
carriers 
There are evidences that SARS-CoV-2 
appears to have been transmitted during the 
incubation period of a patient, in whom the 
illness was brief and nonspecific [10]. 
 
The fact that asymptomatic persons are 
potential sources of SARS-CoV-2 infection 
may warrant a reassessment of transmission 
dynamics of the current outbreak. 
Frequent 
symptoms 
In symptomatic patients, illness may evolve 
over the course of a week or longer, 
beginning with mild symptoms that 
progress (in some cases) to the point of 
dyspnea and shock [11]. Most common 
complaints are fever (almost universal), 
cough, which may or may not be 
productive, whereas myalgia and fatigue 
are common [12]. About 80% of identified 
cases were mild cases [13]. 
  
Severe clinical 
presentations 
Most common complications are: 
1) acute respiratory distress syndrome; 2) 
septic shock; 3) acute kidney injury; 4) 
myocardial injury; 5) secondary bacterial 
and fungal infections; 6) multiorgan failure 
[11,12]. About 14% of identified cases were 
severe and 4.7% critical [13]. 
  
Case fatality 
rate 
The updated case fatality rate of diagnosed 
cases is 2.3, with increasing risk for subjects 
aged 60 or older (3.6% in 60–69 year olds; 
8% in 70–79 year olds, and 14.8% in subjects 
80 or older), and in those with comorbidities 
(case fatality rate in healthy subjects was 
0.9%) [13]. Moreover, mortality rates seem 
to be decreasing over time (15.6%, 1–10 
January, 2020; 5.7%, 11–20 January, 2020; 
1.9%, 21–31 January, 2020; 0.8% after 1 
February, 2020) [13]. 
  
Prevention in 
the general 
population 
For the general public, the best way to 
prevent illness is to avoid being exposed to 
this virus. Face masks do not seem to be as 
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effective in protecting those who are not 
infected, and wearing a mask could be 
useful only when taking care of a person 
with suspected COVID-19 [20]. 
Vaccines There are currently no vaccines against 
coronaviruses, including SARS-CoV-2. 
 
Various vaccine strategies against 
coronavirus, such as using inactivated 
viruses, live-attenuated viruses, viral vector-
based vaccines, subunit vaccines, and 
recombinant proteins are under evaluation. 
However, several months may be required to 
undergo extensive testing to determine its 
safety and efficacy and before it can be widely 
used [21]. 
Therapies 
At present, there is no single specific 
antiviral therapy for SARS-CoV-2 and the 
main treatments are supportive care (e.g., 
supportive therapy and monitoring—
oxygen therapy and fluid management). 
Recombinant interferon (IFN) with ribavirin 
only has limited effects against CoVs 
infection [14]. 
 
Infusions of blood plasma from people who 
have recovered from the COVID-19 could 
represent a valid approach to treat those still 
battling the infection. 
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